ABT-751 With Chemotherapy for Relapsed Pediatric ALL

This study has been terminated.
(The study was stopped due to poor accrual and lack of funding.)
Information provided by (Responsible Party):
Therapeutic Advances in Childhood Leukemia Consortium
ClinicalTrials.gov Identifier:
First received: February 21, 2007
Last updated: November 28, 2012
Last verified: November 2012
This is a phase I/II study of an investigational drug called ABT-751, produced by Abbott Laboratories, given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred). The phase I portion of this study is being done to find the highest dose of ABT-751 that can be given safely in combination with other chemotherapy drugs. A safe dose is one that does not result in unacceptable side effects. After a safe dose for ABT-751 given with chemotherapy has been found, the study will add additional patients to find out if ABT-751 (given at the maximal safe dose) when given with additional chemotherapy is an effective therapy for the treatment of children with relapsed ALL. It is expected that approximately 15-35 children and young adults will take part in this study.

Condition Intervention Phase
Recurrent Pediatric ALL
Relapsed Pediatric ALL
Acute Lymphoblastic Leukemia
Refractory Pediatric ALL
Drug: ABT-751
Drug: dexamethasone
Drug: PEG-asparaginase
Drug: doxorubicin
Drug: cytarabine
Drug: methotrexate
Drug: cyclophosphamide
Drug: 6-thioguanine
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I/II Trial of ABT-751 Combined With Dexamethasone, PEG-asparaginase, and Doxorubicin in Relapsed Acute Lymphoblastic Leukemia (ALL)

Resource links provided by NLM:

Further study details as provided by Therapeutic Advances in Childhood Leukemia Consortium:

Primary Outcome Measures:
  • Dose Limiting Toxicity [ Time Frame: Each dose level is evaluated ] [ Designated as safety issue: Yes ]
  • Maximum Tolerated Dose [ Time Frame: Each dose level is evaluated ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Rate of Remission [ Time Frame: Patients on each dose level will be evaluated for rate of remission. ] [ Designated as safety issue: No ]
  • Pharmacokinetic profile on blood and CSF [ Time Frame: Results will be evaluated upon completion of enrollment to the study. ] [ Designated as safety issue: No ]

Enrollment: 9
Study Start Date: May 2006
Study Completion Date: September 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: ABT-751
    Oral capsule to be given daily for 21 days.
    Drug: dexamethasone
    IV or Oral daily for 14 days
    Drug: PEG-asparaginase
    Intramuscular injection
    Drug: doxorubicin
    IV infusion
    Drug: cytarabine
    Intrathecal dose on day 1
    Drug: methotrexate
    Intrathecal dose
    Drug: cyclophosphamide
    Intravenous dose
    Drug: 6-thioguanine
    Oral dose, course #2
Detailed Description:

All patients will receive the 2 courses of chemotherapy unless medical complications prevent the administration of some of the drugs. Treatment for the first 2 courses of therapy will last about 2 months.

Treatment on this study will consist of a combination of 8 anti-cancer medications. The 8 anticancer medicines are ABT-751, dexamethasone, PEG-asparaginase, doxorubicin, cytarabine (Ara-C), methotrexate (MTX), cyclophosphamide, and 6-thioguanine. All the drugs except ABT-751 are well known anti-cancer drugs and have been used extensively in the treatment of cancer.

During the Phase I portion of this study, when you enroll, you will be given an assigned dose of ABT-751. The dose of ABT-751 will be based on doses given in previous studies done with adults and children. At each dose level of ABT-751, between 3 and 6 children will receive ABT-751 in combination with chemotherapy. If the side effects are not too severe, the next group of children will receive a higher dose. The dose will continue to be increased until we find the dose that causes serious side effects. Your dose of ABT-751 will not be increased. If you have bad side effects, your dose may be decreased.

The dose used during the Phase 2 part of this study will be determined by the outcome of the Phase I study. The highest dose used in Phase I that was tolerated without serious side effects will be the one used in Phase 2.


Ages Eligible for Study:   up to 21 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

This is an abbreviated list...

Inclusion Criteria:

  • Patients must be less than 21 years of age to be participate in this study.
  • Patients must have relapsed acute lymphoblastic leukemia (ALL) without evidence of central nervous system (CNS) disease.
  • Patients must have adequate kidney, heart and liver function.
  • Must be able to swallow capsules.

Exclusion Criteria:

  • Patients who are pregnant or breast feeding.
  • Patients who have an allergy to Asparaginase products or sulfa-containing medications.
  • Patients who have an active uncontrolled infection.
  • Patients who have numbness or tingling in the hands or feet or constipation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00439296

United States, California
City of Hope
Duarte, California, United States, 91010
Childrens Hospital Los Angeles
Los Angeles, California, United States, 90027
Stanford University Medical Center
Palo Alto, California, United States, 94304-1812
UCSF School of Medicine
San Francisco, California, United States, 94143-0106
United States, Florida
University of Miami Cancer Center
Miami, Florida, United States, 33136
United States, Michigan
C.S. Mott Children's Hospital
Ann Arbor, Michigan, United States, 48109-0914
United States, Minnesota
Childrens Hospital & Clinics of Minnesota
Minneapolis, Minnesota, United States, 55404-4597
United States, New York
New York University Medical Center
New York, New York, United States, 10016
United States, Washington
Seattle Children's Hospital
Seattle, Washington, United States, 98105
Sponsors and Collaborators
Therapeutic Advances in Childhood Leukemia Consortium
Study Chair: Paul S Gaynon, MD Childrens Hospital Los Angeles, Therapeutic Advances in Childhood Leukemia Consortium
  More Information

Additional Information:
Responsible Party: Therapeutic Advances in Childhood Leukemia Consortium
ClinicalTrials.gov Identifier: NCT00439296     History of Changes
Other Study ID Numbers: T2005-001 
Study First Received: February 21, 2007
Last Updated: November 28, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Therapeutic Advances in Childhood Leukemia Consortium:
Acute Lymphoblastic Leukemia
Therapeutic Advances in Childhood Leukemia
Relapsed ALL
Refractory ALL
Relapsed pediatric ALL
Refractory pediatric ALL

Additional relevant MeSH terms:
Leukemia, Lymphoid
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type
BB 1101
Dexamethasone 21-phosphate
Dexamethasone acetate
Anti-Inflammatory Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Autonomic Agents
Enzyme Inhibitors
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 26, 2016